Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stake Increased by Emerald Advisers Inc. PA

Share on StockTwits

Emerald Advisers Inc. PA lifted its position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 43.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 580,413 shares of the company’s stock after acquiring an additional 175,049 shares during the period. Emerald Advisers Inc. PA owned approximately 1.45% of Biohaven Pharmaceutical worth $21,795,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its position in Biohaven Pharmaceutical by 10.7% during the 2nd quarter. BlackRock Inc. now owns 2,090,388 shares of the company’s stock worth $82,613,000 after purchasing an additional 201,780 shares in the last quarter. VHCP Management II LLC increased its position in Biohaven Pharmaceutical by 1.8% during the 2nd quarter. VHCP Management II LLC now owns 1,415,391 shares of the company’s stock worth $55,936,000 after purchasing an additional 25,000 shares in the last quarter. FMR LLC increased its position in Biohaven Pharmaceutical by 166.6% during the 2nd quarter. FMR LLC now owns 1,354,064 shares of the company’s stock worth $53,513,000 after purchasing an additional 846,141 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in Biohaven Pharmaceutical by 35.6% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 468,893 shares of the company’s stock worth $17,607,000 after purchasing an additional 123,103 shares in the last quarter. Finally, Northern Trust Corp increased its position in Biohaven Pharmaceutical by 6.6% during the 2nd quarter. Northern Trust Corp now owns 323,923 shares of the company’s stock worth $12,802,000 after purchasing an additional 20,093 shares in the last quarter. 80.81% of the stock is owned by institutional investors.

Shares of NYSE BHVN opened at $36.05 on Thursday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $16.50 and a 52-week high of $44.28.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.68) by $0.67. On average, sell-side analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -5.41 EPS for the current fiscal year.

BHVN has been the subject of several recent research reports. Cantor Fitzgerald upped their price target on shares of Biohaven Pharmaceutical from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, July 12th. Morgan Stanley upped their price target on shares of Biohaven Pharmaceutical from $39.00 to $44.00 and gave the company an “overweight” rating in a research report on Friday, July 13th. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 17th. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, August 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $48.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $47.57.

Biohaven Pharmaceutical Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Read More: Market Capitalization and Individual Investors

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply